FDA Offers Guidance on Targeting Rare, Molecular Subsets of Diseases

Drug Industry Daily
A A
New FDA draft guidance published last week breaks down the use of targeted therapies in low-frequency and rare molecular disease subsets.

To View This Article:

Login

Subscribe To Drug Industry Daily